Results 31 to 40 of about 16,441 (147)

Mechanistic Basis for the Differential Effects of Rivaroxaban and Apixaban on Global Tests of Coagulation

TH Open, 2018
Rivaroxaban and apixaban are both small molecules that reversibly inhibit factor Xa. Compared with rivaroxaban, apixaban has minimal effects on the prothrombin time and activated partial thromboplastin time.
Paul Y. Kim, Calvin H. Yeh, Brian J. Dale, Beverly A. Leslie, Alan R. Stafford, James C. Fredenburgh, Jack Hirsh, Jeffrey I. Weitz   +7 more
doaj   +1 more source

New Hybrid Tetrahydropyrrolo[3,2,1-ij]quinolin-1-ylidene-2-thioxothiazolidin-4-ones as New Inhibitors of Factor Xa and Factor XIa: Design, Synthesis, and In Silico and Experimental Evaluation

Molecules, 2023
Despite extensive research in the field of thrombotic diseases, the prevention of blood clots remains an important area of study. Therefore, the development of new anticoagulant drugs with better therapeutic profiles and fewer side effects to combat ...
Nadezhda P. Novichikhina, Alexander S. Shestakov, Svetlana M. Medvedeva, Anna M. Lagutina, Mikhail Yu. Krysin, Nadezhda A. Podoplelova, Mikhail A. Panteleev, Ivan S. Ilin, Alexey V. Sulimov, Anna S. Tashchilova, Vladimir B. Sulimov, Athina Geronikaki, Khidmet S. Shikhaliev   +12 more
doaj   +1 more source

Direct oral anticoagulant blood level monitoring in daily practice

Thrombosis Update, 2021
Introduction: Routine monitoring is not required in direct oral anticoagulant (DOAC) treatment, yet it is frequently performed. Guidance on the interpretation and management of DOAC level measurements is lacking and it is key to investigate which ...
R. Bavalia, J.E. Veenhuizen, R.C.C. Hengeveld, D. Braeken, A.J.W. Gulpen, H. Ten Cate, S. Middeldorp, Y.M.C. Henskens, B.A. Hutten, M. Coppens, A.K. Stroobants   +10 more
doaj   +1 more source

Factor Xa Inhibitors [PDF]

, 2016
Factor Xa represents an attractive target for antithrombotic drugs as blockade of factor Xa permits inhibition of both the extrinsic and intrinsic coagulation pathways. Several factor Xa inhibitors, such as rivaroxaban, apixaban and edoxaban, have been approved for certain conditions, and are also in clinical development for other indications.
Eduard Shantsila, Gregory YH Lip
openaire   +1 more source

Management of heparin-induced thrombocytopenia with factor xa inhibitors: A systematic review

Thrombosis Update
Heparin-induced thrombocytopenia (HIT) is a rare but severe prothrombotic disorder that develops in patients exposed to heparin products. Diagnosis is associated with significant morbidity and mortality.
Colton Jones, Abiodun Idowu, Elvis Obomanu, Raymond Smith, Karecia Byfield, Avinash Ramkissoon, Kevin Bryan Lo, Ryan Mayo   +7 more
doaj   +1 more source

Is There an Alternative Oral Anticoagulation to Vitamin-K-Antagonists for Patients with Mechanical Aortic Valve Replacement? – A Literature Review

Cardiology and Therapy
Current guidelines exclusively recommend vitamin-K-antagonists (VKA) as anticoagulation for patients after mechanical aortic valve replacement due to the increased postoperative risk of valve thrombosis and thrombo-embolism.
Stephen Gerfer, Thorsten Wahlers, Elmar Kuhn   +2 more
doaj   +1 more source

Assessing Safety of Direct Thrombin Inhibitors, Direct Factor Xa Inhibitors and Vitamin K Antagonists in Patients with Atrial Fibrillation: A Nation-Wide Propensity Score Matched Cohort from Sweden

Clinical Epidemiology, 2020
Marie Linder,1 Anastasia Iliadou Nyman,2,3 Helle Kieler,1 Bengt Danielsson,2 Natalia Borg,2 Marcus Gry,2 Julius Collin2 1Centre for Pharmacoepidemiology, Karolinska Institutet, T2, Karolinska University Hospital, Stockholm, Sweden; 2The National Board of
Linder M, Iliadou Nyman A, Kieler H, Danielsson B, Borg N, Gry M, Collin J   +6 more
doaj  

Real-world andexanet alfa utilization and the association between delay in administration due to hospital transfer and all-cause inpatient mortality

Research and Practice in Thrombosis and Haemostasis
Background: Evaluations of andexanet alfa for the reversal of factor Xa inhibitor-associated bleeding have been small, with cohorts drawn from single/limited sites.
Huiqiao Fan, Youssef Bessada, Craig I. Coleman   +2 more
doaj   +1 more source

Pharmacodynamics and Pharmacokinetics of oral factor Xa inhibitors

Clinical Pharmacology: Advances and Applications, 2015
Pontus B Persson Institute of Vegetative Physiology, Berlin, GermanyApixaban and rivaroxaban are oral factor Xa inhibitors. In a recent issue of Clinical Pharmacology: Advances and Applications, Frost et al compare apixaban (2.5 mg, twice daily) to ...
Persson PB
doaj  

Velhos e novos anticoagulantes orais. Perspetiva farmacológica

Revista Portuguesa de Cardiologia, 2012
Resumo: A terapêutica anticoagulante oral está em mudança. A varfarina e o acenocumarol constituem ainda o padrão anticoagulante oral em muitos contextos clínicos.
Pedro Marques da Silva
doaj   +1 more source